Rheumatoid amosanin gabbai
| Rheumatoid amosanin gabbai | |
|---|---|
 | |
Description (en)  | |
| Iri |
arthritis (en) , autoimmune disease (en) , chronic condition (en) , collagen disease (en) , autoimmune disease of musculoskeletal system (en) cuta |
| Specialty (en) |
rheumatology (en) immunology (en) |
| Symptoms and signs (en) |
chronic secondary musculoskeletal pain (en) |
| Genetic association (en) |
SPRED2 (en) , CCR6 (en) , DPP4 (en) , CDK5RAP2 (en) , GRM5 (en) , CASTOR1 (en) , IL2RA (en) , KIF5A (en) , ACOXL (en) , ANKRD55 (en) , ARID5B (en) , ATG5 (en) , MACIR (en) , CD226 (en) , CD40 (en) , CDK6 (en) , CTLA4 (en) , EOMES (en) , GATA3 (en) , IL2RB (en) , IL6R (en) , JAZF1 (en) , LOC100506023 (en) , NFKBIE (en) , PADI4 (en) , PLCL2 (en) , PPIL4 (en) , PRKCH (en) , PTPN2 (en) , RAD51B (en) , RASGRP1 (en) , REL (en) , SFTPD (en) , STAT4 (en) , SYNGR1 (en) , TEC (en) , TYK2 (en) , WDFY4 (en) , UBASH3A (en) , ARL15 (en) , RTKN2 (en) , ALPL (en) , PDE3A (en) , SLCO1C1 (en) , SPSB1 (en) , SLC6A11 (en) , ENOX1 (en) , MDGA2 (en) , PSMA4 (en) , RCHY1 (en) , ETFA (en) , ANXA3 (en) , PLD4 (en) , GCH1 (en) , MICA (en) , BLK (en) , TRHDE (en) , ARHGEF3 (en) , CD247 (en) , ELMO1 (en) , IFI16 (en) , IRF5 (en) da SH2B3 (en) |
| Medical treatment (en) | |
| Magani |
ibuprofen (en) , chloroquine (en) , valdecoxib (en) , methotrexate (en) , (+-)-flurbiprofen (en) , D-penicillamine (en) , (RS)-ketoprofen (en) , cyclosporine (en) , oxaprozin (en) , indomethacin (en) , Diclofenac (en) , (RS)-fenoprofen (en) , sulindac (en) , aurothioglucose (en) , adalimumab (en) , azathioprine (en) , tolmetin (en) , (RS)-etodolac (en) , diflunisal (en) , hydroxychloroquine (en) , auranofin (en) , naproxen (en) , etanercept (en) , piroxicam (en) , thalidomide (en) , sulfasalazine (en) , celecoxib (en) , nabumetone (en) , anakinra (en) , captopril (en) , leflunomide (en) , enalapril (en) , zinare, aspirin (en) , tolmetin (en) , (RS)-etodolac (en) , piroxicam (en) , sulindac (en) , frentizole (en) , (RS)-fenoprofen (en) , hydroxychloroquine (en) , (RS)-ketoprofen (en) , nabumetone (en) , (+-)-flurbiprofen (en) da methylprednisolone (en) |
| Identifier (en) | |
| ICD-10-CM | M06.9 |
| ICD-9-CM | 714.0 |
| OMIM | 180300 |
| DiseasesDB | 11506 |
| MedlinePlus | 000431 |
| eMedicine | 000431 |
| MeSH | D001172 |
| Disease Ontology ID | DOID:7148 |
Rheumatoid amosanin gabbai (RA) cuta ce ta autoimmune na dogon lokaci wacce ke shafar haɗin gwiwa.[1] Yawanci yana haifar da dumi, kumbura, da ƙumburi mai raɗaɗi.[1] Raɗaɗi da taurin kai sukan tsananta bayan hutu. Mafi yawanci, wuyan hannu da hannaye suna da hannu, tare da haɗin gwiwa iri ɗaya galibi suna shiga bangarorin biyu na jiki.[1] Haka kuma cutar na iya shafar sauran sassan jiki.[1] Wannan na iya haifar da ƙarancin adadin ƙwayoyin jini, kumburi a kusa da huhu, da kumburin zuciya.[1] Zazzabi da ƙarancin kuzari na iya kasancewa.[1] Sau da yawa, bayyanar cututtuka na zuwa a hankali cikin makonni zuwa watanni.[2]
Duk da yake abin da ke haifar da cututtukan cututtuka na rheumatoid ba a bayyana ba, an yi imanin ya ƙunshi haɗuwa da kwayoyin halitta da abubuwan muhalli.[1] Tsarin da ke ciki ya ƙunshi tsarin garkuwar jiki da ke kai hari ga gidajen abinci.[1] Wannan yana haifar da kumburi da kauri na haɗin capsule na gwiwa.[1] Hakanan yana shafar ƙashin da ke ciki da guringuntsi.[1] Ana yin ganewar asali ne yawanci akan alamomi da alamun mutum.[2] Hoton X-ray da gwajin dakin gwaje-gwaje na iya goyan bayan ganewar asali ko ware wasu cututtuka masu irin wannan alamun.[1] Sauran cututtuka da zasu iya gabatarwa irin wannan sun hada da lupus erythematosus na tsarin jiki, psoriatic arthritis, da fibromyalgia da sauransu.[2]
Makasudin maganin shine don rage zafi, rage kumburi, da inganta aikin mutum gaba ɗaya.[3] Ana iya taimakawa wannan ta hanyar daidaita hutu da motsa jiki, amfani da splint da braces, ko amfani da na'urorin taimako.[1][4][5] Ana amfani da magungunan zafi, steroids, da NSAIDs akai-akai don taimakawa tare da bayyanar cututtuka.[1] Ana iya amfani da magungunan antirheumatic masu gyara cuta (DMARDs), irin su hydroxychloroquine da methotrexate, don ƙoƙarin rage ci gaban cuta.[1] Ana iya amfani da DMARD na halitta lokacin da cuta ba ta amsa wasu jiyya ba.[6] Duk da haka, suna iya samun mafi girman adadin rashin illa.[7] Tiyata don gyarawa, maye gurbin, ko haɗa haɗin gwiwa na iya taimakawa a wasu yanayi.[1] Yawancin magungunan madadin magani ba su da goyan bayan shaida.[8][9]
RA yana shafar kusan mutane miliyan 24.5 kamar na 2015.[10] Wannan yana tsakanin 0.5 da 1% na manya a cikin ƙasashen da suka ci gaba tare da 5 da 50 a cikin 100,000 mutane suna tasowa yanayin kowace shekara.[11] Farawa ya fi yawa a lokacin tsakiyar shekaru kuma mata suna shafar sau 2.5 akai-akai fiye da maza.[1] Ya haifar da mutuwar 38,000 a cikin 2013, daga mutuwar 28,000 a 1990.[12] An yi bayanin farko na RA a 1800 ta Augustin Jacob Landré-Beauvais (1772-1840) na Paris.[13] Kalmar rheumatoid arthritis gabbai ta dogara ne akan Hellenanci don haɗin ruwa da kumburi.[14]
Manazarta
[gyara sashe | gyara masomin]- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 "Handout on Health: Rheumatoid Arthritis". National Institute of Arthritis and Musculoskeletal and Skin Diseases. August 2014. Archived from the original on June 30, 2015. Retrieved July 2, 2015.
- ↑ 2.0 2.1 2.2 Majithia V, Geraci SA (November 2007). "Rheumatoid arthritis: diagnosis and management". The American Journal of Medicine. 120 (11): 936–9. doi:10.1016/j.amjmed.2007.04.005. PMID 17976416.
- ↑ "Rheumatoid arthritis in adults: management: recommendations: Guidance and guidelines". NICE. December 2015. Archived from the original on 2017-04-16.
- ↑ Rausch Osthoff AK, Juhl CB, Knittle K, Dagfinrud H, Hurkmans E, Braun J, et al. (2018-12-04). "Effects of exercise and physical activity promotion: meta-analysis informing the 2018 EULAR recommendations for physical activity in people with rheumatoid arthritis, spondyloarthritis and hip/knee osteoarthritis". RMD Open. 4 (2): e000713. doi:10.1136/rmdopen-2018-000713. PMC 6307596. PMID 30622734.
- ↑ Park Y, Chang M (January 2016). "Effects of rehabilitation for pain relief in patients with rheumatoid arthritis: a systematic review". Journal of Physical Therapy Science. 28 (1): 304–8. doi:10.1589/jpts.28.304. PMC 4756025. PMID 26957779.
- ↑ Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T (January 2016). "2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis". Arthritis & Rheumatology. 68 (1): 1–26. doi:10.1002/art.39480. PMID 26545940.
- ↑ Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, Filippini G, Skoetz N, Francis D, Lopes LC, Guyatt GH, Schmitt J, La Mantia L, Weberschock T, Roos JF, Siebert H, Hershan S, Lunn MP, Tugwell P, Buchbinder R (February 2011). "Adverse effects of biologics: a network meta-analysis and Cochrane overview". The Cochrane Database of Systematic Reviews (2): CD008794. doi:10.1002/14651858.CD008794.pub2. PMC 7173749. PMID 21328309.
- ↑ Efthimiou P, Kukar M (March 2010). "Complementary and alternative medicine use in rheumatoid arthritis: proposed mechanism of action and efficacy of commonly used modalities". Rheumatology International. 30 (5): 571–86. doi:10.1007/s00296-009-1206-y. PMID 19876631. S2CID 21179821.
- ↑ "Rheumatoid Arthritis and Complementary Health Approaches". National Center for Complementary and Integrative Health. January 2006. Archived from the original on July 5, 2015. Retrieved July 1, 2015.
- ↑ Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, et al. (GBD 2015 Disease and Injury Incidence and Prevalence Collaborators) (October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577. PMID 27733282.
- ↑ Smolen JS, Aletaha D, McInnes IB (October 2016). "Rheumatoid arthritis" (PDF). Lancet. 388 (10055): 2023–2038. doi:10.1016/S0140-6736(16)30173-8. PMID 27156434. S2CID 37973054.
- ↑ GBD 2013 Mortality Causes of Death Collaborators (January 2015). "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013". Lancet. 385 (9963): 117–71. doi:10.1016/S0140-6736(14)61682-2. PMC 4340604. PMID 25530442.
- ↑ Landré-Beauvais AJ (1800). La goutte asthénique primitive (doctoral thesis). Paris.
- ↑ Paget, Stephen A.; Lockshin, Michael D.; Loebl, Suzanne (2002). The Hospital for Special Surgery Rheumatoid Arthritis Handbook Everything You Need to Know. New York: John Wiley & Sons. p. 32. ISBN 9780471223344. Archived from the original on 2017-02-22.